Category: 201811-20-3

On July 22, 2004, Takemura, Makoto; Ota, Toshiharu; Uoto, Koichi; Kawakami, Katsuhiro; Yoshino, Toshiharu; Yokomizo, Yoshihiro; Yoshikawa, Kenji published a patent.COA of Formula: C11H14N2O5 The title of the patent was Preparation of 1,2-phenylenediamine amides as activated blood coagulation factor X inhibitors. And the patent contained the following:

The title thiazolopyridinecarboxylic acid 1,2-phenylenediamine amides with general formula of Q1-Q2-A0-Q3-A00-Q4 [wherein Q1 = (un)substituted cyclohydrocarbyl, heterocyclyl, etc.; Q2 = a single bond, alkylene, alkenylene, etc.; Q3 = (un)substituted phenylene or any other (hetero)arylene; Q4 = (un)substituted aryl, arylalkenyl, etc.; A0 = (un)substituted CONH or CSNH; A00 = OCH2, (un)substituted CONH, SO2NH, etc.] or salts, solvates, or N-oxides thereof are prepared as activated blood coagulation factor X inhibitors. For example, the compound I was prepared in a multi-step synthesis. I inhibited human FXa with IC50 of 1.9 nM. The compounds are useful for the treatment of blood coagulation, thrombosis, embolism, etc. (no data). The experimental process involved the reaction of tert-Butyl (4-hydroxy-2-nitrophenyl)carbamate(cas: 201811-20-3).COA of Formula: C11H14N2O5

The Article related to phenylene amine amide preparation activated blood coagulation factor inhibitor, preparation thiazole carboxamide treatment blood coagulation thrombosis embolism human, Heterocyclic Compounds (More Than One Hetero Atom): Thiazoles, Isothiazoles and other aspects.COA of Formula: C11H14N2O5

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On August 20, 2020, Cao, Ping; Zhang, Chao; Bishop, Michael J. published a patent.Computed Properties of 201811-20-3 The title of the patent was Preparation of novel pyridinylpyrimidines as FGFR inhibitors for the treatment of cancer. And the patent contained the following:

The invention provides the title compounds I [each R1-R5 = (independently) H, F, Cl, Br, alkyl, etc.; R6 = (CH2)0-5CH:CH2, (CH2)0-5CCH, NHCO(CH2)0-5CH:CH2, etc.; Linker = (un)substituted alkyl, COalkyl, CO2alkyl, etc.] or optically pure stereoisomers, solvates, or pharmaceutically acceptable salts thereof with broad inhibitory activity against all FGFR isoforms, and inhibitors with selective inhibition against FGFR4. E.g., a multi-step synthesis of II, starting from 4-amino-3-nitro-phenol and tert-Bu 3-iodoazetidine-1-carboxylate, was described. Exemplified compounds I were evaluated for FGFR inhibition (data given). These novel pyridinylpyrimidine-based FGFR inhibitors, or their derivatives, have strong potential to be used to treat cancer. The experimental process involved the reaction of tert-Butyl (4-hydroxy-2-nitrophenyl)carbamate(cas: 201811-20-3).Computed Properties of 201811-20-3

The Article related to pyridinylpyrimidine preparation fgfr4 inhibitor antitumor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Computed Properties of 201811-20-3

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On December 29, 1998, Duggan, Mark E.; Egbertson, Melissa S.; Hartman, George D.; Young, Steven D.; Ihle, Nathan C. published a patent.Safety of tert-Butyl (4-hydroxy-2-nitrophenyl)carbamate The title of the patent was Preparation of 4-[(4-piperazinobeznoyl)amino]phenyl(oxy)alkanoates as fibrinogen receptor antagonists. And the patent contained the following:

XYZAB [I; A = (un)substituted (hetero)arylene; B = O(CH2)mCO2R9, (CH2)nCO2R9, CHR8(CH2)pCO2R9, OCHR8(CH2)pCO2R9; R8 = H, OH, alkyl, alkoxy, aryl, etc.; R9 = H, (ar)alkyl, aryl, acylalkyl, etc.; X = (un)substituted heterocyclyl or -heteroaryl; Y = (un)substituted heterocyclylene or -(hetero)arylene; Z = bond, NH, CONH, CO, CH2CH2, etc.; m = 1-3; n,p = 0-3] were prepared Thus, 4-(H2N)C6H4CO2Me was cyclocondensed with HN(CH2CH2Cl)2 and the N-protected and saponified product amidated by 4-BrC6H4NH2 to give the bromobenzanilide which was condensed with CH2:CHCO2Me and the product converted in 3 addnl. steps to 4-RC6H4CONHC6H4(CH2CH2CO2H)-4 (R = piperazino). Data for biol. activity of I were given. The experimental process involved the reaction of tert-Butyl (4-hydroxy-2-nitrophenyl)carbamate(cas: 201811-20-3).Safety of tert-Butyl (4-hydroxy-2-nitrophenyl)carbamate

The Article related to piperazinobeznoylaminophenylalkanoate preparation fibrinogen receptor antagonist, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Safety of tert-Butyl (4-hydroxy-2-nitrophenyl)carbamate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On May 13, 2004, Jones, Peter; Burli, Roland W.; Jiang, Chun; McMinn, Dustin L. published a patent.Category: esters-buliding-blocks The title of the patent was Preparation of arylcarbonylaminopyrrolylcarbonylaminopyrrolylbenzimidazoles and related compounds as antiinfectives.. And the patent contained the following:

Title compounds [I; Ar = (substituted) (fused) Ph, heteroaryl; Q = N, CH, CR6; ≤2 Q = N; R1-R4 = H, alkyl; R5 = H, (substituted) alkyl, heteroalkyl; R6 = (substituted) alkyl, OR5, N(R5)2, O2CR5, NCOR5, Cl, F, Br], were prepared Thus, title compound (II) (preparation given) showed a min. inhibitory concentration of ≤4 μg/mL against Staphylococcus aureus 33591. The experimental process involved the reaction of tert-Butyl (4-hydroxy-2-nitrophenyl)carbamate(cas: 201811-20-3).Category: esters-buliding-blocks

The Article related to arylcarbonylaminopyrrolylcarbonylaminopyrrolylbenzimidazole preparation antibacterial, benzimidazole arylcarbonylaminopyrrolylcarbonylaminopyrrolyl preparation antibacterial, pyrrolylcarbamoylpyrrole arylaminocarbonyl imidazoazine preparation antiinfective and other aspects.Category: esters-buliding-blocks

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On January 8, 1998, Duggan, Mark E.; Egbertson, Melissa S.; Hartman, George D.; Young, Steven D.; Ihle, Nathan C. published a patent.COA of Formula: C11H14N2O5 The title of the patent was Preparation of heterocyclyl-substituted phenoxyalkanoic acids as fibrinogen receptor antagonists. And the patent contained the following:

The title compounds X-Y-Z-A-B [I; X = (un)substituted 5-7- membered aromatic or nonaromatic ring, having 1-3 heteroatoms selected from N, O, and S, (un)substituted 9-10 membered fused aromatic or nonaromatic ring, having 1-3 heteroatoms selected from N, O, and S; Y = (un)substituted 5-6 membered aromatic or nonaromatic ring, having 0-3 heteroatoms selected from N, O, and S; XY = II, III, IV, V; Z = C(O)NR4, N(R4)C(O), CH2CH2, CH:CH, etc.; R4 = H, C1-4 alkyl, C3-6 cycloalkyl; A = (un)substituted 5-6 membered aromatic ring, having 0-3 heteroatoms selected from N, O, and S, 9-10 membered fused aromatic ring having 0-3 heteroatoms (N, O, and S); B = C(CH2)mCO2R9, (CH2)nCO2R9, CH(R8)(CH2)pCO2R9, OCH(R8)(CH2)pCO2R9 (wherein m = 1-3; n = 0-3; p = 0-3; R8 = H, aryl, amino, etc.; R9 = H, aryl, C1-8 alkyl, etc.)], useful in inhibiting the binding of fibrinogen to blood platelets, inhibiting the aggregation of blood platelets, treating thrombus or embolus formation, inhibiting osteoclast mediated bone resorption, inhibiting angiogenesis, and in inhibiting tumor growth, were prepared and formulated. Thus, a few-step detailed synthesis of the acid VI which showed IC50 in the range between 10 nM and 50 mM against ADP-stimulated platelet aggregation, was described. The experimental process involved the reaction of tert-Butyl (4-hydroxy-2-nitrophenyl)carbamate(cas: 201811-20-3).COA of Formula: C11H14N2O5

The Article related to phenoxyalkanoic acid preparation formulation fibrinogen antagonist, platelet aggregation inhibitor phenoxyalkanoic acid preparation, bone resorption inhibitor phenoxyalkanoic acid preparation, thrombus treatment phenoxyalkanoic acid preparation formulation, embolus treatment phenoxyalkanoic acid preparation formulation and other aspects.COA of Formula: C11H14N2O5

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics